http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022093832-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92ebee933d7b49d9a67bd55f31ce03c0
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-007
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
filingDate 2021-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c863277b08c0173b0c2846073c4945b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db65f3286db64955f05d7fc4e5be685b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c20e5e954fbecd6eb0315e97099d9799
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbe39fe5c7c552fdbd00a6b1f3987532
publicationDate 2022-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022093832-A1
titleOfInvention Implant to treat retinal vein occlusion
abstract Intraocular implants include a proximal end, a distal end, and a lumen, disposed between the proximal end and the distal end. When implanted into an eye, the proximal end is in fluid communication with a retinal vein of the eye and the distal end is in fluid communication with a choroid of the eye. Via this fluid communication, the intraocular implants treat retinal vein occlusion.
priorityDate 2020-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009182421-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010010416-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016256318-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014081195-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005244462-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91670
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395300

Total number of triples: 21.